Duopharma Biotech Bhd (XKLS:7148) Total Stockholders Equity: RM786.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:7148 Duopharma Biotech Bhd XKLS:7148
79 GF Score
Price RM1.24
GF Value RM1.49
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd Total Stockholders Equity?

Duopharma Biotech Bhd XKLS:7148 -0.80% 79 Total Stockholders Equity is RM786.1 Mil as of Jun. 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 79/100 and a GF Value™ of RM1.49 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Duopharma Biotech Bhd's Total Stockholders Equity for the quarter that ended in Jun. 2026 was RM786.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Duopharma Biotech Bhd's Book Value per Share for the quarter that ended in Jun. 2026 was RM0.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Duopharma Biotech Bhd's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.60.

Duopharma Biotech Bhd  (XKLS:7148) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Duopharma Biotech Bhd's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(786.139-0)/961.942
=0.82

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Duopharma Biotech Bhd's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(134.963 + 336.635) / 786.139
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Total Stockholders Equity Related Terms

Duopharma Biotech Bhd Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Total Stockholders Equity Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 624.00 655.22 687.12 709.15 757.62

Duopharma Biotech Bhd Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 736.09 744.12 757.62 757.35 786.14
XKLS:7148
79GF Score
Duopharma Biotech Bhd XKLS:7148
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of RM786.1 Mil mean?
Duopharma Biotech Bhd (XKLS:7148) has a Total Stockholders Equity of RM786.1 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Total Stockholders Equity too high?
Duopharma Biotech Bhd's current Total Stockholders Equity is RM786.1 Mil. Overall, Duopharma Biotech Bhd has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Total Stockholders Equity compare to ZTS and UTHR?
Duopharma Biotech Bhd's Total Stockholders Equity of RM786.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Total Stockholders Equity is RM786.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.49, compared to a current price of RM1.24 — trading 16.8% below its estimated fair value. The current Total Stockholders Equity is RM786.1 Mil. Duopharma Biotech Bhd's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Total Stockholders Equity is RM786.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.24 is trading 16.8% below its estimated GF Value™ of RM1.49. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • Total Stockholders Equity: RM786.1 Mil
  • GF Value™: RM1.49 vs. price of RM1.24 (16.8% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
79GF Score

Get the complete analysis for XKLS:7148

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.24
Price
RM1.49
GF Value